R3TA (Retatrutide): Metabolic Research Overview

Triple receptor agonist: Retatrutide simultaneously targets GLP-1, GIP, and gluc

R3TA (retatrutide, LY3437943) is a triple hormone receptor agonist that simultaneously targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. It represents one of the newest compounds in metabolic and obesity research. This article provides a research-only overview.

Chemical Identity

Retatrutide is a 39-amino acid peptide with a modified backbone that enables simultaneous agonism at three distinct receptors. It is an investigational compound — not FDA-approved — sold exclusively for in vitro and laboratory research.

Triple Receptor Mechanism

Retatrutide's unique mechanism involves three signaling pathways:

• GLP-1 receptor agonism — similar to semaglutide and liraglutide; studied for effects on appetite regulation and glucose metabolism in cell-based assays
• GIP receptor agonism — studied for insulin secretion modulation and adipose tissue signaling
• Glucagon receptor agonism — studied for effects on hepatic glucose production and energy expenditure

The combined triple agonism is hypothesized to produce synergistic metabolic effects in research models, beyond what single or dual receptor agonists achieve.

Research Applications

Obesity and Weight Management Research

Retatrutide has generated significant research interest due to its potential in metabolic research models. Preclinical and clinical trial data have been published examining its effects on body composition and metabolic markers. Key research areas:

• Adipose tissue signaling and lipolysis studies
• Hepatic glucose production and insulin sensitivity models
• Appetite regulation and satiety signaling in hypothalamic cell models
• Energy expenditure and thermogenesis research

Comparative Research with Other GLP-1 Agonists

Researchers compare Retatrutide with other metabolic research compounds:

• Semaglutide — single GLP-1 receptor agonist
• Tirzepatide — dual GLP-1/GIP receptor agonist
• Retatrutide — triple GLP-1/GIP/glucagon receptor agonist

Each targets a different combination of receptors, making them valuable for comparative metabolic signaling studies.

Type 2 Diabetes Research Models

Retatrutide is studied in the context of insulin resistance and beta-cell function in pancreatic cell models, examining its triple receptor mechanism in glucose homeostasis.

Sourcing Retatrutide for Research

• Purity — see lot COA (HPLC/MS); no catalog-wide %
• Identity — mass spectrometry confirmation essential for this complex peptide
• Storage — -20°C as lyophilized powder; protect from light
• COA — lot-specific COA with HPLC and MS data